Extended Data Fig. 1: (a) Percentage of patients with ≥50% liver fat reduction and (b) percentage of patients achieving liver fat normalization at Week 12 for TERN-501 monotherapy groups (Efficacy Analysis Set). | Nature Medicine

Extended Data Fig. 1: (a) Percentage of patients with ≥50% liver fat reduction and (b) percentage of patients achieving liver fat normalization at Week 12 for TERN-501 monotherapy groups (Efficacy Analysis Set).

From: TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial

Extended Data Fig. 1

*P < 0.05; ***P < 0.001 for TERN-501 monotherapy versus placebo. Normalization of liver fat equates to magnetic resonance imaging proton density fat fraction <5%. Percentage of patients with ≥50% liver fat reduction: TERN-501 1 mg P = 0.3018; TERN-501 3 mg P = 0.0675; TERN-501 6 mg P = 0.0005. Percentage of patients achieving liver fat normalization: TERN-501 6 mg P = 0.0134. P-values obtained using a chi-square test. Comparison between groups was conducted at the 2-sided, 0.05 level of significance, and no adjustments for multiplicity were made.

Source data

Back to article page